DDInter1563 DDInter1694
Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.
Sodium zirconium cyclosilicate is approved as the trade product Lokelma developed by AstraZeneca - an insoluble, non-absorbed sodium zirconium silicate, formulated as a powder for oral suspension that acts as a highly selective potassium removing agent. It is administered orally and is odorless, tasteless, and stable at room temperature. Approval of the medication is supported by data from three double-blind, placebo-controlled trials and two open-label trials which showed that the onset of action was approximately 1.0 hour and the median time to achieving normal potassium levels in the blood was 2.2 hours, with 92% of patients achieving normal potassium levels within 48 hours following administration. The treatment effect was maintained for up to 12 months.
Raltegravir {u} (Compound) binds {v} (Gene) UGT1A1
Raltegravir {u} (Compound) upregulates {v} (Gene) HSPB1
Raltegravir {u} (Compound) downregulates {v} (Gene) INPP1
Raltegravir {u} (Compound) causes {v} (Side Effect) Mediastinal disorder
Raltegravir {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rabeprazole
Raltegravir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lorlatinib
Raltegravir {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Magnesium oxide
Raltegravir {u} may lead to a major life threatening interaction when taken with {v} Zinc gluconate
Raltegravir {u} may lead to a major life threatening interaction when taken with {v} Aluminum hydroxide
Raltegravir (Compound) binds UGT1A1 (Gene)
Raltegravir (Compound) upregulates HSPB1 (Gene)
Raltegravir (Compound) downregulates INPP1 (Gene)
Raltegravir (Compound) causes Mediastinal disorder (Side Effect)
Raltegravir may cause a minor interaction that can limit clinical effects when taken with Rabeprazole
Raltegravir may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Raltegravir may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide
Raltegravir may lead to a major life threatening interaction when taken with Zinc gluconate
Raltegravir may lead to a major life threatening interaction when taken with Aluminum hydroxide